Innovation
AACR 23 Posters
GTC presented abstracts at AACR 2023 GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach
April 20, 2023 10:49 am
Innovation
Read More »
Innovation
Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development
Baltimore, MD and Irvine, CA, April 13, 2023, Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative
April 13, 2023 7:00 am
Innovation
In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership
Combining Longitudinal Real-World Data and Clinical Genomics Data Will Enable a More Precise Approach to Cancer Care and Research NEW YORK – COTA, Inc., an
March 8, 2023 5:05 am
Innovation
Genomic Testing Cooperative Implementing AI, Molecular Profiling to Improve Cancer Diagnosis
CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative
November 3, 2022 9:02 am
Article
Case Study: VEXAS Syndrome
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
June 8, 2022 11:20 am
Genomic Testing Cooperative to Reveal “Liquid Trace™” at ASCO, a Liquid Biopsy Test that Combines Cell-Free DNA with Targeted Transcriptome and to Present Data on its Advanced AI for the Diagnosis of Hematologic and Solid Tumors
Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO)
June 1, 2022 4:00 am
Innovation
Genomic Testing Cooperative Hematology Profile Plus, Solid Tumor Profile Plus, and Liquid Biopsy Profiles Receive CE-IVD Mark
IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as
May 25, 2022 3:55 am
Innovation
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms
Abstract Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap
February 1, 2022 9:54 am
GTC at ASH 2021
GTC is excited to be exhibiting at ASH for the first time and look forward to meeting people in person. Our booth # 3440 and would
November 18, 2021 11:39 am
Innovation
Do not Accept partial results about PH-Like Acute Lymphoblastic Leukemia
Distinguishing PH-like acute lymphoblastic leukemia (ALL) from other types of ALL relies on full evaluation of the molecular abnormalities in the leukemic cells. Order GTC
October 1, 2019 10:16 pm